| Literature DB >> 36078880 |
Chang-Lun Huang1,2, Chun-Min Chen3, Wei-Heng Hung1, Ya-Fu Cheng1, Ruei-Ping Hong1, Bing-Yen Wang1,4,5,6,7,8, Ching-Yuan Cheng1,4.
Abstract
Mediastinal lymph dissection in esophagectomy for patients with esophageal cancer is important. The dissection of recurrent laryngeal nerve (RLN) lymph nodes could cause RLN injury, vocal cord palsy, pneumonia, and respiratory failure. This retrospective study aimed to evaluate the effects of intraoperative RLN monitoring in esophagectomy and mediastinal lymph node dissection in preventing RLN injury and vocal cord palsy. This study included 75 patients who underwent minimally invasive esophagectomy and mediastinal lymph node dissection for esophageal cancer with (38 patients) and without (37 patients) IONM at Changhua Christian Hospital from 2015 to 2020. The surgical and clinical outcomes were reviewed. Patients in the IONM group had more advanced clinical T status, shorter operation time (570 vs. 633 min, p = 0.007), and less blood loss (100 mL vs. 150 mL, p = 0.019). The IONM group had significantly less postoperative vocal palsy (10.5% vs. 37.8%, p = 0.006) and pneumonia (13.2% vs. 37.8%, p = 0.014) than that in the non-IONM group. IONM was an independent factor for less postoperative vocal cord palsy that was related to postoperative 2-year survival. This study demonstrated that IONM could reduce the incidence of postoperative vocal cord palsy and pneumonia.Entities:
Keywords: esophageal cancer; esophagectomy; intraoperative nerve monitoring; recurrent laryngeal nerve; vocal cord palsy
Year: 2022 PMID: 36078880 PMCID: PMC9456676 DOI: 10.3390/jcm11174949
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Patient characteristics.
| IONM | Non-IONM | ||||
|---|---|---|---|---|---|
| Age (mean ± SD) | 60.18 ± 8.99 | 56.16 ± 9.78 | 0.068 | ||
| Gender | |||||
| Male | 34 | 89% | 34 | 92% | 0.719 |
| Female | 4 | 11% | 3 | 8% | |
| History of H and N cancer | |||||
| No | 34 | 89% | 30 | 81% | 0.304 |
| Yes | 4 | 11% | 7 | 19% | |
| Neoadjuvant CCRT | |||||
| No | 23 | 61% | 17 | 46% | 0.206 |
| Yes | 15 | 39% | 20 | 54% | |
| cT stage | |||||
| 1 | 6 | 16% | 2 | 5% | 0.038 |
| 2 | 9 | 24% | 21 | 57% | |
| 3 | 21 | 55% | 13 | 35% | |
| 4 | 2 | 5% | 1 | 3% | |
| cN stage | |||||
| 0 | 16 | 42% | 9 | 24% | 0.331 |
| 1 | 12 | 32% | 15 | 41% | |
| 2 | 6 | 16% | 10 | 27% | |
| 3 | 4 | 11% | 3 | 8% | |
| Tumor location | |||||
| Upper thoracic/middle thoracic | 27 | 71% | 24 | 65% | 0.566 |
| Lower thoracic/EG junction | 11 | 29% | 13 | 35% | |
| Cell type | |||||
| Squamous cell carcinoma | 33 | 87% | 34 | 92% | 0.716 |
| Adenocarcinoma | 4 | 11% | 2 | 5% | |
| Others | 1 | 3% | 1 | 3% | |
IONM, intraoperative nerve monitoring; H and N cancer, head and neck cancer; CCRT, concurrent chemoradiation therapy; EG junction, esophagogastric junction.
Surgical outcome.
| IONM | Non-IONM | |||||
|---|---|---|---|---|---|---|
| % | % | |||||
| Operation time, minutes | Median (IQR) | 570 | (533–644) | 633 | (586–688) | 0.007 |
| Blood loss, ml | Median (IQR) | 100 | (50–150) | 150 | (100–200) | 0.019 |
| ICU LOS, days | Mean ± SD | 4.6 ± 2.6 | 5.9 ± 4.2 | 0.096 | ||
| Hospital LOS, days | Mean ± SD | 21.1 ± 9.7 | 19.8 ± 7.7 | 0.515 | ||
| pT stage | ||||||
| 0 | 6 | 16% | 10 | 27% | 0.624 | |
| Tis | 0 | 0% | 1 | 3% | ||
| 1 | 7 | 18% | 4 | 11% | ||
| 2 | 8 | 21% | 5 | 14% | ||
| 3 | 16 | 42% | 16 | 43% | ||
| 4 | 1 | 3% | 1 | 3% | ||
| pN stage | ||||||
| 0 | 19 | 50% | 17 | 46% | 0.337 | |
| 1 | 8 | 21% | 13 | 35% | ||
| 2 | 11 | 29% | 7 | 19% | ||
| Harvested MLN | 30.0 ± 12.9 | 28.9 ± 8.7 | 0.670 | |||
| Positive MLN | 1.0 ± 1.6 | 0.7 ± 1.0 | 0.391 | |||
| Ratio of positive MLN | 2.97% | 2.53% | ||||
| Harvested TLN | 41.9 ± 13.9 | 41.5 ± 11.7 | 0.898 | |||
| Positive TLN | 1.4 ± 1.8 | 1.3 ± 1.7 | 0.710 | |||
| Ratio of positive TLN | 3.23% | 3.01% | ||||
| Harvested right RLN LN | 3.6 ± 2.4 | 3.3 ± 2.3 | 0.572 | |||
| Harvested left RLN LN | 3.1 ± 3.2 | 1.8 ± 2.0 | 0.043 | |||
IONM, intraoperative nerve monitoring; IQR, interquartile range; LOS, length of stay; MLN, mediastinal lymph nodes; TLN, total lymph nodes; RLN, recurrent laryngeal nerve; LN, lymph nodes.
Postoeprative morbidity.
| IONM | non-IONM | ||||
|---|---|---|---|---|---|
|
| % |
| % | ||
| Vocal cord palsy | 4 | 10.5% | 14 | 37.8% | 0.006 |
| Right/left/bilateral | 2/2/0 | 3/10/1 | |||
| Pneumonia | 5 | 13.2% | 14 | 37.8% | 0.014 |
| Other complications | |||||
| Anastomosis leakage | 5 | 28% | 3 | 14% | 0.298 |
| Pneumothorax/air leak | 1 | 6% | 1 | 5% | 0.911 |
| Chylothorax | 2 | 11% | 0 | 0% | 0.117 |
| Chyloabdomen | 1 | 6% | 1 | 5% | 0.911 |
| Loculated pleural effusion | 3 | 17% | 2 | 10% | 0.506 |
| Respiratory failure | 0 | 0% | 1 | 5% | 0.348 |
IONM, intraoperative nerve monitoring.
Figure 1Percentage of IONM use and palsy observed by survival status.
Figure 2Two-year survival in patients with thoracic esophageal cancer between those (A) with and without IONM, (B) with and without vocal cord palsy, and (C) with or without IONM + palsy.
Hazard ratios for death (analysis from time of surgery) using the backward elimination (BE).
| HR | 95.0% CI | ||
|---|---|---|---|
| Vocal cord palsy (with) | 2.98 | (1.32–6.71) | 0.008 |
| Age (year) | 1.05 | (1.01–1.08) | 0.016 |
| pT(Tis + T1a/b + T2) | 7.25 | (2.09–25.17) | 0.002 |
| pT(T3 + T4) | 12.53 | (3.62–43.35) | 0.000 |
| Neoadjuvant CCRT | 8.37 | (3.59–19.52) | 0.000 |
| ICU duration (day) | 1.11 | (1.00–1.22) | 0.040 |
HR, hazard ratio; CI, confidence interval